Nail Fungus: The Rule No Wording Gets Around

what does the non-grase listing actually say about nails and scalp?

21 CFR 310.545(a)(22)(iii) answers this in one clause: it places within the non-GRASE category — not generally recognized as safe and effective, the bar an over-the-counter drug ingredient has to clear — "Any ingredient(s) labeled with claims or directions for use on the scalp or on the nails," per the regulation's current text at Cornell's Legal Information Institute. Clearing GRASE for use on skin doesn't carry the ingredient over to the nail plate or scalp.

310.545(b) then makes the failure automatic rather than a matter of degree. A product carrying that kind of nail- or scalp-directed label is treated as a new drug requiring an approved application under section 505, and separately as misbranded under section 502 when no such application exists — two violations from one label sentence, with nothing graded in between.

No amount of careful copywriting moves a nail claim back inside GRASE.

how old is this rule and why is it still binding today?

This isn't a new or untested position — it dates to a September 2, 1993 final rule, and 310.545(a)(22)(iii) has been in continuous effect since March 2, 1994. The CARES Act, the 2020 law that restructured FDA's over-the-counter drug review system, carried the prohibition forward instead of letting it lapse.

FDA's own footnote traces the chain: conditions in 310.545 that were in effect the day before the CARES Act's enactment were carried into a standing administrative order, now filed as Non-Monograph Conditions NM900, Order ID OTC 000007, per FDA's April 2026 warning letter to Chemco Corporation. We counted the distance between that 1993 rulemaking and the Chemco letter that still cites it: thirty-three years, unbroken.

The same durability shows up outside this niche. 'Balance' and 'support' don't rescue thyroid copy once a diagnosis gets named, for the same structural reason — the underlying rule doesn't age out just because the product category is different.

what status does a nail-fungus topical hold if it ships anyway?

It becomes an unapproved new drug the moment it ships — not a supplement with pushy marketing, but a misbranded drug under two FD&C Act sections at once. FDA's April 7, 2026 letter to Chemco Corporation applied exactly this framework to "PRO Nail FUNGUS KILLER," charging violations of sections 505(a) and 301(d) plus misbranding under 502(ee), because the product's undecylenic acid was directed at the nail — a use 310.545(a)(22)(iii) already closed.

FDA didn't need a testimonial to make its case; it read the label and the picture as one document. The letter cites copy stating the product "helps stop and eliminate fungal infections . . . under nail tips where accessible with applicator drops," and separately cites the image on the front label of the dropper applying the drug directly to the nail, per FDA's warning letter to Chemco Corporation.

Most operators in this niche assume the picture is decoration and only the words are legally live. FDA's own evidence trail says otherwise: the applicator-tip image did as much work in the Chemco letter as the sentence beside it. If your creative pairs compliant wording with a nail-touching product shot, you haven't removed the risk — you've just handed FDA a second exhibit.

does moving the claim to an oral supplement open a route?

No — fungal infection is a disease, and moving the same promise from a cream to a capsule doesn't manufacture a structure/function claim where none exists. Dietary supplements get a safe harbor for claims about the body's normal operation, not for claims to eliminate an infection anywhere in the body, on the nail or off it.

FDA has already tested this exact move. Its April 18, 2024 letter to APG SEVEN, INC. treated two oral products, Hongotrap and Honbacterol, as new drugs over Spanish-language copy claiming to eliminate fungus and fungal strains from the body, per FDA's warning letter to APG SEVEN.

Changing the format didn't change the disease.

why does the bloodstream angle exist and why does it still fail?

The bloodstream narrative exists because the topical route is closed by law, not because anyone found evidence the fungus travels there. Ads in this niche routinely assert that the infection isn't really on the nail at all — that it lives in the blood or gut, which is why a cream can never reach it and only an oral product can reach the "root." FDA's letter to APG SEVEN, INC. caught this narrative on the page it cited: "Las infecciones de los hongos no son sólo a nivel de la piel, sino también a nivel sanguíneo" — in FDA's own English rendering, fungal infections aren't confined to the skin; they also reach the blood. We've catalogued how often this exact villain line runs across the niche's video sales letters in Nail Fungus VSL Angles: 76% of Its Villain Lines Are Fungal, and the commercial appeal is obvious: a systemic cause justifies an oral SKU and a bigger cart than a $12 topical ever could.

It fails for the same reason the topical does.

Relocating the mechanism doesn't relocate the legal question. Whether the claim says "on the nail" or "in the blood," it still promises to treat, cure or eliminate a fungal infection — disease-claim ground with no structure/function exit, regardless of which organ the copy points to.

which nail-adjacent claims are left standing?

Some claims survive, but none of them touch the nail. The clearest template on record is Kramer Laboratories' 2018 matter with the National Advertising Division (NAD), the ad industry's self-regulatory body, over "Fungi-Nail Toe & Foot" — the brand kept its name and its athlete's-foot claims, and gave up every claim pointed at the nail itself.

To close the matter, per FTC's resolution letter to NAD, Kramer modified its packaging to depict "a healthy nail with fungal infection on the skin surrounding the nail or between the toes," added "CURES Most Athlete's Foot" to the front panel, and added a side-panel line stating the product isn't for nail or scalp fungus. The nail stayed off the table; the skin next to it didn't.

The dividing line isn't the intensity of the language, it's where the claim points. The same shape shows up in cognitive-supplement copy, where absentmindedness is allowed and memory loss is not — see Absentmindedness Is Allowed. Memory Loss Is Not. — except here the line runs between the skin and the nail plate rather than between a normal complaint and a diagnosis.

One thing we could not verify: current US prevalence of onychomycosis. CDC's fungal-nail-infection page returned an access-denied response when we tried to load it directly, so treat any prevalence figure circulating in this niche's ad copy as unconfirmed until it's checked against CDC's fungal diseases pages or NIH/MedlinePlus directly.

how do platform rules stack on top of the regulatory floor?

Platform policy adds a second ceiling on top of the legal one, and it isn't more forgiving. Google classifies conditions requiring long-term management, which includes onychomycosis, inside its Health sensitive interest category, so a nail-fungus campaign loses Customer Match, lookalikes and remarketing lists and runs only on predefined Google audiences. If your campaign targets the US, expect that restriction the moment nail fungus is the topic, not after a complaint.

Meta's health and wellness policy separately bans two devices this niche's creative leans on hardest: statements of inferiority about physical appearance, and clickbait promising a specific outcome inside a set timeframe without disclaimers. "Clear nails in three weeks" sits inside both prohibitions at once, before the FDA or FTC analysis even starts.

A refund promise compounds the exposure rather than sitting outside it. A guarantee's wording is itself a claim, as we cover in Your Money-Back Guarantee Wording Is a Claim, and "guaranteed clear nails or your money back" reads to a platform reviewer as the same outcome promise stated twice.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Joint Pain Relief Band: What It Is and What It Is Not, Peptide Manufacturing Market: Read Before You Rely on It, Nutraceutical Manufacturing Business for Sale, Supplement Distribution Aubange: What the Evidence Shows, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.